Background. The prognostic impact of pathologic response to preoperative therapy on patients with duodenal adenocarcinoma (DA) and ampullary adenocarcinoma (AMPA) has not been established. Methods. A retrospective review of 266 patients who underwent curative resection for DA (n = 97) or AMPA (n = 169) during 1993-2015 was performed. For patients who underwent preoperative therapy, the pathologic response was systematically evaluated and classified as major (0-49% of viable residual tumor cells) or minor (C 50% of viable residual tumor cells). Uni-and multivariable analyses were performed to identify predictors of pathologic response and disease-specific survival (DSS). Results. For the 79 patients treated with preoperative therapy (DA: n = 34; AMPA: n = 45), concomitant use of radiation (80%, 67/79) was the sole independent predictor of major pathologic response (odds ratio [OR] 8.17; 95% confidence interval [CI] 1.85-58.2; P = 0.005). The patients with major pathologic response had a better 5-year DSS rate than the patients with minor pathologic response (DA: 65 vs 25%; P = 0.028; AMPA: 85 vs 43%; P = 0.016). In the multivariable analysis of DSS for the 79 patients who underwent preoperative therapy, major pathologic response was the sole predictor of improved DSS (hazard ratio [HR] 2.88; 95% CI 1.41-5.98; P = 0.004). In the multivariable analysis of DSS for the entire cohort, pathologic stage 2 or lower was the sole predictor of better DSS. Conclusion. The major pathologic response to preoperative therapy predicted improved DSS after resection of DA and AMPA and might represent a new prognosticator after resection of DA and AMPA.
ABSTRACT
Background. The prognostic impact of pathologic response to preoperative therapy on patients with duodenal adenocarcinoma (DA) and ampullary adenocarcinoma (AMPA) has not been established. Methods. A retrospective review of 266 patients who underwent curative resection for DA (n = 97) or AMPA (n = 169) during 1993-2015 was performed. For patients who underwent preoperative therapy, the pathologic response was systematically evaluated and classified as major (0-49% of viable residual tumor cells) or minor (C 50% of viable residual tumor cells). Uni-and multivariable analyses were performed to identify predictors of pathologic response and disease-specific survival (DSS). Results. For the 79 patients treated with preoperative therapy (DA: n = 34; AMPA: n = 45), concomitant use of radiation (80%, 67/79) was the sole independent predictor of major pathologic response (odds ratio [OR] 8.17; 95% confidence interval [CI] 1.85-58.2; P = 0.005). The patients with major pathologic response had a better 5-year DSS rate than the patients with minor pathologic response (DA: 65 vs 25%; P = 0.028; AMPA: 85 vs 43%; P = 0.016). In the multivariable analysis of DSS for the 79 patients who underwent preoperative therapy, major pathologic response was the sole predictor of improved DSS (hazard ratio [HR] 2.88; 95% CI 1.41-5.98; P = 0.004). In the multivariable analysis of DSS for the entire cohort, pathologic stage 2 or lower was the sole predictor of better DSS. Conclusion. The major pathologic response to preoperative therapy predicted improved DSS after resection of DA and AMPA and might represent a new prognosticator after resection of DA and AMPA.
Periampullary cancers are a heterogeneous group of malignancies that include all neoplasms derived from the pancreaticobilio-digestive junction. Cancers usually classified as periampullary include ductal cancers from the pancreatic head, cholangiocarcinomas from the common bile duct, duodenal cancers, and ampullary cancers. 1 Of these, duodenal adenocarcinoma (DA) and ampullary adenocarcinoma (AMPA) are rare, accounting for respectively 0.4 and 2% of gastrointestinal cancers. 2, 3 Histopathologically, AMPAs are further subclassified as intestinal or pancreaticobiliary type. 4 Whereas several reports have suggested that pancreaticobiliary-type AMPA has a worse prognosis than intestinal-type AMPA, [5] [6] [7] other reports show no impact of subtype on outcome. 3, 8 Whereas resection to date remains the only potentially curative treatment for DA and AMPA, the precise role of perioperative therapy in the treatment of these diseases has not been established. 9 Because prospective randomized studies of postoperative adjuvant chemotherapy for periampullary adenocarcinoma have failed to show a survival advantage of postoperative chemotherapy for patients with DA and AMPA, 8, 10 postoperative chemotherapy options for these diseases are extrapolated from the literature on pancreatic and colon cancer. Similarly, due to the rarity of DA and AMPA, little has been reported in the literature concerning the impact of preoperative therapy for these diseases. 2, 3 Previous retrospective study regarding localized AMPA demonstrated the safety and feasibility of preoperative chemotherapy, chemoradiation, or both but suggested a limited role for the routine administration of preoperative therapies before intended resection. 11 In clinical practice at our institution, patients with DA or AMPA who frequently have bulky disease, regional adenopathy, or both are likely to undergo preoperative therapy as recommended by the multidisciplinary care team. 12 When preoperative therapy is used, pathologic response (as shown in other gastrointestinal cancers) to preoperative therapy correlates significantly with prognosis after surgery and can be used as a prognosticator. However, whether pathologic response to preoperative therapy correlates with the prognosis for patients with DA and AMPA remains unclear. [13] [14] [15] [16] The current study aimed to determine the prognostic value of pathologic response to preoperative therapy of patients with DA and AMPA.
MATERIALS AND METHODS

Study Population
The Institutional Review Board of The University of Texas MD Anderson Cancer Center approved this study protocol (PA16-0530). A prospectively maintained hepatopancreatobiliary database of the Department of Surgical Oncology was reviewed to identify patients who underwent curative resection for DA and AMPA between January 1993 and December 2015. Patients with periampullary cancer considered to represent primary biliary or pancreatic adenocarcinoma and patients with Lynch syndrome diagnosed by Amsterdam 2 criteria were excluded from the study.
A total of 266 patients (97 with DA; 169 with AMPA) were identified (Fig. 1) . Among these patients, we identified patients treated with preoperative therapy followed by curative resection. The following data were extracted from electronic patient medical records: sex, age, body mass index, presence of diabetes mellitus, preoperative therapy characteristics (chemotherapy regimen and duration, and dose of radiation), operative characteristics (surgical procedure and margin status [R0: all margins clear of tumor on microscopic examination; R1: cancer on inked common bile duct, pancreatic neck, or superior mesenteric artery margin on microscopic examination, but margins clear of tumor on macroscopic examination]), [17] [18] [19] primary tumor characteristics (differentiation, subtypes of AMPA [intestinal or pancreaticobiliary], 4 perineural and lymphovascular invasion), lymph node metastases, pathologic stage based on the American Joint Committee on Cancer staging system, 7th edition, 20 and postoperative therapy characteristics.
Ampullary adenocarcinoma with mixed intestinal and pancreaticobiliary components was categorized on the basis of the predominant component. 5 Pathologic response to preoperative therapy was systematically evaluated according to the method of Ribero et al. 21 and reported as major or minor according to the mean of the percentage of viable residual cancer cells within each tumor (major response: 0-49% of viable residual cancer cells; minor response: C 50% of viable residual cancer cells). 13 Hematoxylin-eosin-stained sections were reviewed by two gastrointestinal pathologists (H.W. and J.Z.). The pathologists were blinded with respect to clinical information, treatment regimen, outcome, and goal of the study.
Treatment
Decisions about the treatment strategy for each patient, including whether to use preoperative therapy, were made at a weekly specialty multidisciplinary conference. In general, patients were considered candidates for upfront resection when they were medically fit and able to undergo macroscopically curative resection. Patients with preexisting comorbidity, disease perceived to be biologically advanced due to one or more well-defined clinical parameters (e.g., regional lymphadenopathy, advanced T stage, indeterminate liver/lung lesions) or treatment of disease believed to be pancreatic ductal adenocarcinoma on the basis of existing clinical workup 11, 22, 23 underwent preoperative therapy (chemotherapy alone or chemoradiation). 11, 12, 24 Preoperative chemotherapy consisted primarily of regimens containing fluorouracil, capecitabine, or gemcitabine administered for 4-6 months. 25, 26 When administered, external beam radiation was delivered using either a hypofractionated regimen (10 fractions) or standard fractionated regimen (28 fractions) with concurrent fluorouracil, capecitabine, or gemcitabine. External beam radiation was delivered 5 days per week (Monday-Friday). Computed tomography (CT)-based three-dimensional conformal treatment planning was routinely used.
After preoperative therapy, the patient was restaged, and surgery was recommended in the absence of clinical or radiographic evidence of disease progression if the patient maintained an adequate performance status and if a complete resection could be performed. Postoperative chemotherapy alone or chemoradiation was administered selectively based on the decision by a multidisciplinary team of medical, surgical, and radiation oncologists.
In general, these therapeutic methods were recommended for patients with high-risk features associated with their cancer, such as positive lymph nodes, advanced T stage, R1 margin status, poor tumor differentiation, or lymphovascular/perineural invasion. 11 Patients were followed routinely after surgery with history, physical examination, laboratory evaluations, and axial imaging every 3-4 months for the first 2 years, then every 4-6 months for the subsequent 3 years.
Statistical Analyses
Continuous variables were compared using the Wilcoxon rank-sum test, and categorical variables were compared using the Chi square test. For evaluation of pathologic response predictors, uni-and multivariable analyses were performed by logistic regression analysis. Disease-specific survival (DSS) was measured from the date of resection to the date of death due to disease (DA or AMPA) or the last follow-up visit. Patients who died of an unrelated cause were censored at the time of death. Survival curves were generated using the Kaplan-Meier method, and differences in survival were evaluated with the log-rank test. Uni-and multivariable analyses to identify predictors of DSS were performed by Cox proportional hazards regression models. Variables with a P value lower than 0.1 in univariable analysis were entered into each multivariable analysis. A P value lower than 0.05 was considered statistically significant in all analyses. Statistical analyses were performed with IBM SPSS software (version 23.0; SPSS Inc., Chicago, IL, USA). Table 1 lists the clinicopathologic and operative data for the 97 patients with DA and the 169 patients with AMPA. The patients with AMPA were more likely than the patients with DA to be male. During the current study period, 97 patients (41 with DA; 56 with AMPA) were planned to receive preoperative therapy followed by curative resection. However, of these patients, 18 (7 with DA; 11 with AMPA) did not undergo the planned resection due to disease progression (4 with DA; 6 with AMPA) and poor general status (3 with DA; 5 with AMPA). These 18 patients were therefore excluded from the analysis.
RESULTS
Patient Characteristics
The final study cohort consisted of 79 patients treated with preoperative therapy and curative resection (34 with DA; 45 with AMPA). Among these patients those with AMPA versus DA were more likely to receive chemoradiation and less likely to receive chemotherapy alone (Table 1) . Among the patients with AMPA undergoing preoperative therapy followed by resection, 13% (6/45) of the cases were considered preoperatively pancreatic ductal adenocarcinoma, which was significantly more frequent than DA (P = 0.027, 0/34,).
The rate of major pathologic response after preoperative therapy did not differ significantly between the patients with AMPA (64%) and those with DA (47%) (P = 0.122). The two groups did not differ significantly in terms of preoperative chemotherapy regimen or duration. Among the 169 patients with AMPA, histologic subtyping (intestinal vs pancreaticobiliary) was determined for 151 patients (89%), 35 of whom underwent preoperative therapy. No significant difference was observed among the patients with DA, intestinal AMPA, and pancreaticobiliary AMPA with respect to preoperative chemotherapy regimen (Table S1 ). Patients with AMPA were more likely than those with DA to undergo pancreaticoduodenectomy. Among the patients with DA, pathologic stage 3 disease was predominant, whereas among the patients with AMPA, pathologic stage 2 disease was predominant. Table S2 lists the clinicopathologic characteristics of the patients who did (n = 79) and did not (n = 187) undergo preoperative therapy. The patients who underwent preoperative therapy had significantly more poorly differentiated tumors. No other significant difference was identified between the two groups.
Predictors of Pathologic Response
A major pathologic response was observed in 45 (57%) of the 79 patients who underwent preoperative therapy. Table 2 lists the results from the uni-and multivariable analyses of potential predictors of major pathologic response in patients who underwent preoperative therapy. The singular independent predictor of major pathologic response was concomitant use of radiation. The patients with AMPA who underwent preoperative therapy exhibited no significant difference with respect to the rate of major pathologic response by histopathologic subtype ( Table 2) .
Predictors of Survival
The median follow-up period was 57 months (range 1.0-267 months). In the multivariable analysis of potential predictors of DSS after curative resection in the entire cohort (n = 266), the sole independent predictor of worse DSS was pathologic stage 3 or higher (Table S3) . Preoperative therapy independent of pathologic response was not a significant predictor of DSS in the entire cohort or in the subgroups of patients with DA and AMPA (Fig. S1) . Similarly, the presence of postoperative therapy was not a significant predictor of DSS in the entire cohort or in the subgroups of patients undergoing preoperative therapy (Table S3, 3) . However, among the 79 patients treated with preoperative therapy, DSS was significantly worse for the patients with minor versus major pathologic response (Fig. 1b) . Similar results were found in the subgroup analyses of patients with DA (Fig. 1c) or AMPA (Fig. 1d) . In the multivariable analysis of factors associated with DSS after curative resection in patients undergoing preoperative therapy, major pathologic response was identified as the sole independent predictor of better DSS (Table 3) .
Among the 187 patients without preoperative therapy, multivariable analysis of factors associated with DSS after curative resection identified absence of diabetes mellitus, Wilcoxon rank-sum test R0 resection, and pathologic stage 2 or lower as the independent predictors of better DSS (Table S4) .
DISCUSSION
This study found that among patients with DA and AMPA who underwent preoperative therapy, those with major versus minor pathologic response had a better 5-year DSS rate overall and in the DA and AMPA subgroups. Previous reports have shown the prognostic effects of pathologic response to preoperative therapy in patients with several other gastrointestinal cancers, [13] [14] [15] [16] but to the best of our knowledge, this is the first report to show the impact of pathologic response to preoperative therapy on survival after curative resection of DA and AMPA.
We also found that in our cohort with resected DA and AMPA, concurrent radiotherapy was an independent predictor of major pathologic response among the patients who underwent preoperative therapy. Previous reports have hinted toward an optimal pathologic response of chemoradiation for DA and AMPA. Yeung et al. 27 reported a phase 2 study demonstrating the efficacy of preoperative chemoradiation for DA, which led to a resectability rate of 80% and showed extensive necrosis and hyalinization in all patients undergoing resection. Others have shown with AMPA patients that downstaging secondary to preoperative chemoradiation was achieved for 67% of the patients (28%, pathologically complete response). 28 Furthermore, patients with AMPA significantly more often received preoperative chemoradiation than patients with DA. This is consistent with a previous report suggesting a favorable chemoradiation sensitivity of AMPA. 28 Previous studies of unresectable biliary tract cancer have suggested that chemoradiation produced better long-term outcomes than chemotherapy alone. 29 In recent years, a number of reports have shown the feasibility and tolerability of chemoradiation for locally advanced biliary tract cancer and DA. 19, 30, 31 In the current study, histopathologic subtype of AMPA (intestinal or pancreaticobiliary) was not a predictor of major pathologic response to preoperative therapy. Previous studies addressing this topic have produced inconsistent results. Some have shown that histomorphologic subtypes predict response to specific chemotherapy, 9, 32 whereas others have shown no impact of subtype on chemotherapy response. 3, 8, 33 In the current study, the multivariable analysis of potential predictors of DSS in the entire cohort showed that preoperative therapy did not have a positive impact on prognosis, which is consistent with the published literature. 11 However, this finding must be viewed in light of a possible selection bias. Resectable patients with advanced disease were thought to benefit possibly from preoperative therapy due their comparatively higher disease burden. In fact, pathologic review of specimens after preoperative therapy and resection confirmed that poorly differentiated tumors were more common among patients with preoperative therapy than among patients without preoperative therapy. A prospective randomized trial would provide robust evidence regarding the prognostic impact of preoperative therapy for DA and AMPA, but conducting such a trial would be challenging due to the rarity of these diseases.
2,3
Our results also suggested that the impact of traditional predictors of DSS after resection in patients with DA and AMPA might be mitigated by the effects of modern preoperative therapy. The multivariable analysis of DSS for the 187 patients without preoperative therapy identified R0 resection and pathologic stage 2 or lower as the independent predictors of improved DSS. Conversely, in the multivariable analysis of DSS for the 79 patients who underwent preoperative therapy, major pathologic response was the sole predictor of improved DSS instead of such traditional factors. Further research is required for an optimal choice of postoperative therapy based on pathologic response to preoperative therapy rather than traditional prognosticators, which may aid clinicians in stratifying the need for postoperative therapy.
This study had several limitations. First, it was limited by its retrospective nature and associated biases, including selection bias because the analyzed cohort was limited to patients who completed preoperative therapy followed by planned curative resection (79 of 97, 81%). Second, histopathologic subtyping was not determined in a proportion of the patients with AMPA (18/169, 11%), and the population of patients with histopathologic subtyping who also were treated with preoperative therapy was limited (n = 35). Thus, our finding that histopathologic subtype of AMPA was not associated with pathologic response to preoperative therapy (Table 2 ) might potentially be underpowered to detect a difference. Third, our analyses grouped DA and AMPA together due to the rarity of these clinicopathologic disease entities, similar to previously published series. [1] [2] [3] Fourth, among the patients treated with preoperative therapy, those with AMPA were less likely than those with DA to receive chemotherapy alone and more likely than those with DA to receive chemoradiation. The higher rate of chemoradiation in the AMPA versus the DA group may have been due in part to consideration that some AMPA was pancreatic ductal adenocarcinoma preoperatively 34 and concerns regarding duodenal toxicity in concomitant radiation when DA was treated. 35 Finally, the current study did not include information concerning the genotype of tumors, including information about KRAS status, and also lacked information regarding microsatellite instability status.
In the field of surgery for colorectal liver metastases, previous literature has demonstrated an association between mutant KRAS and suboptimal pathologic response to preoperative chemotherapy. 36 In addition, a study on AMPA 37 identified KRAS mutation as an independent predictor of poor prognosis after curative resection, and others have suggested that microsatellite instability is associated with improved survival for patients with AMPA and DA. 38, 39 Further research is needed to identify biomarkers that can predict the pathologic response to preoperative therapy of patients with AMPA and DA. This not only would allow patients who would benefit from preoperative therapy to be stratified toward receiving it, but it also would help to avoid unnecessary preoperative therapy for patients who do not derive a survival advantage from it.
In conclusion, for patients with DA and AMPA treated with preoperative therapy followed by curative resection, pathologic response predicted postoperative DSS. Delivery of radiotherapy concurrently with preoperative chemotherapy was associated with major pathologic response. Pathologic response to preoperative therapy may be a new predictor of prognosis after resection of DA and AMPA. 
